Blog
Immuno-Oncology BioA: Pre-Existing ADAs Affecting PK
When administering human monoclonal antibodies, reconstituted human proteins, and antibody drug conjugates (ADCs), anti-drug antibodies (ADAs) can form and affect the Biotherapeutic’s exposure, bioavailability, and pharmacodynamic effects. The qualities of these ADAs – such as their specificity, magnitude, timing, maturity, and affinity – can impact pharmacokinetics (PK) and pharmacodynamics (PD). Challenges Presented by ADAs in…
Understanding the Issues with ADA Assays
The biotech industry is rapidly modifying and developing biotherapeutics into complex large molecules with specificity moieties and multiple functional domains to produce a specific biological method of action. (ADC, ACC, Bi-specific antibodies, Fusion proteins, recombinant-modified proteins, etc.) Therefore, developing LBA assays to detect the immunogenicity of these biotherapeutics is becoming very complex due to this…
Sword Bio Appoints David Osband as EVP, Sales & Marketing
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for pre-clinical and clinical trials, announces the appointment of David Osband as EVP, Sales & Marketing. David joins Sword with a proven track record in the contract research space. Most notably, he was an owner of Cambridge Biomedical,…
Sword Bio Appoints Matthew Langevin as Chief Operating Officer
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs from development to clinical trials, announces the appointment of Matthew Langevin as Chief Operating Officer. Matt joins Sword with exceptional experience and a proven track record in the contract research space. Most notably, he was Co-Founder of BioAgilytix,…